Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Fallopian Tube Neoplasms 10Ovarian Neoplasms 7Endometrial Neoplasms 5Breast Neoplasms 4Prostatic Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Triple Negative Breast Neoplasms 2Osteosarcoma 2Neuroendocrine Tumors 2Neuroblastoma 2Neoplasms 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Glioma 2Ependymoma 2Xanthogranuloma, Juvenile 1Wilms Tumor 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Recurrent Ovarian High Grade Serous Adenocarcinoma 1Recurrence 1

Interventions

tivozanib 2durvalumab 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Gemcitabine 2Cisplatin 2olaparib 1atezolizumab 1Stents 1Oxaliplatin 1Nivolumab 1Leucovorin 1Ipilimumab 1Folfox protocol 1Fluorouracil 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bile Duct Neoplasms × olaparib × 30 days × Clear all
NCT04042831 2026-05-15

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

Academic and Community Cancer Research United

Phase 2 Active not recruiting
32 enrolled 15 charts
Gastrointestinal

Bile Duct Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡